Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US 0 10.02.2026 06:26 Thehindubusinessline.com Under the agreement, Lupin and its US unit will pay Astellas $90 million, including a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027 Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
